Background Human cancers are heterogenic and thus response to immune checkpoint inhibitors (ICIs) such as anti-PD-1 or anti-PD-L1 antibody treatments can be vastly different, with only 20% of treated patients responding and some initial responders developing resistance. However, the mechanism of...
The binding of T cell immune checkpoint proteins programmed death 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to their ligands allows immune evasion by tumours. The development of therapeutic antibodies, termed checkpoint inhibitors
近10年来,以程序性细胞死亡受体1(programmed cell death protein 1,PD1)/程序性死亡受体配体1(programmed death-ligand 1,PD-L1)为代表的免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)在肺癌治疗中取得了显著进展。PD1/PD-L1单抗通过阻断PD1/PD-...
3. Alsaab HO et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Front Pharmacol. 2017; 8: 1-15. 4. Gong et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review ...
Fig. 2: PD-L1 inhibitors secreted from VV-iPDL1/GM-infected cells bind to PD-L1 on tumor cells and immune cells. aMC38 tumor cells were infected with VV-RFP, VV-iPDL1/GM at an MOI = 0.5, or PBS for 24 h. The percentage of IgG Fc+population representing iPDL1 (soluble ...
PD-1/PD-L1检查点抑制剂不再是简单“增强”免疫反应,而是让肿瘤发病过程中出现缺陷的免疫系统“恢复正常”。“恢复正常”的免疫系统可以使部分患者实现长期生存获益,由于单药PD-1/PD-L1检查点抑制剂的客观缓解率仅为20%左右,使得获益人群有限。 (A Paradigm Shift in Cancer Immunotherapy: From Enhancement to No...
(PD-L1) axis plays a key role in physiological immune homeostasis and putatively served as a means through which cancer cells evade the immune system [4]. The development and application of immune checkpoint inhibitors that block PD-1/PD-L1 interaction result in very durable responses and ...
As hypothesized based on their mechanism of action, combination of PD-1 and CTLA-4 blockers has been successful in increasing the response rates and median survival time in cancer patients. Nivolumab plus ipilimumab combination has been approved for 3 indications including, metastatic melanoma, advanc...
Targeting the programmed cell death protein 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) interaction has become an established strategy for cancer immunotherapy. Although hundreds of small-molecule, peptide, and peptidomimetic inhibitors have been proposed in recent years, only a limited number ...
Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors. Arch. Immunol. Ther. Exp. 2020, 68, 36. [Google Scholar] [CrossRef] Xin Yu, J.; Hodge, J.P.; Oliva, C.; Neftelinov, S.T.; Hubbard-Lucey, V.M.; ...